Smith & Nephew is a London-headquartered medical technology manufacturer founded in 1856, employing 11,000 people globally.
Is this your business? Add your evidence →
Smith & Nephew reports genuine 63% absolute emissions cuts (Scope 1+2) and 59% Scope 3 reductions since 2021, backed by third-party verification. Energy transition is real but hampered by reliance on unbundled renewable energy certificates. Nature impact, water stewardship, and SBTi validation remain underdeveloped.
Smith & Nephew scores 53/100 (Making progress) on SINK's independent climate assessment, scored from public data only. Fees pay for the review, never the result. Last verified October 2026.
That places Smith & Nephew joint 80th of 847 companies scored, and 1st of 19 in Healthcare / Pharmaceuticals.
Smith & Nephew is the highest-scoring healthcare / pharmaceuticals company we've rated.
Among the 19 major healthcare / pharmaceuticals brands we've scored, Smith & Nephew sits 1st of 19.
Its three lowest-scoring questions, and what the evidence didn't show.
No TNFD disclosure identified in FY2022–2024 filings.
No quantified reduction targets, no independently verified stewardship programme, no watershed engagement.
Reduction-driven, no heavy offset reliance.
A score changes when the evidence does. We use new published evidence at the next rescore. Evidence that isn't public can count through an evidence review.
Use this score in tenders
Send the link, or the one-page score sheet. It links back to this page and every source. Free.
Open the score sheet →Add your evidence, £99
Scored low because little is published? Send us your evidence. A person reviews it and your score reflects what you really do. Done within 5 working days.
Evidence review →Go tender-ready, £495 a year
A yearly rescore, a check of up to 25 key suppliers and a score badge for your website (coming soon).
Get in touch →Strongest on Carbon Footprint — Operations and Emissions Trajectory (8/10, 8/10). Weakest on Nature & Biodiversity Impact and Water Impact (3/10, 4/10).
Smith & Nephew leads its sector. These are the next 3 down.
AstraZeneca has cut operational emissions 77.5% since 2015 and locked in science-based net-zero targets, but absolute supply chain emissions are rising 18.6% from baseline.
See the breakdown →GSK has credible climate infrastructure: verified Scope 1&2 data, SBTi-validated net-zero to 2045, and sector-leading nature disclosures.
See the breakdown →Haleon reports comprehensively on Scope 1+2 emissions and has achieved 100% renewable electricity, with verified 55% net reduction versus 2020.
See the breakdown →Smith & Nephew's score has moved from 51 to 53 across 2 recorded reviews, up 2 points.
Aggregator-citation sweep: broker citations replaced with the primary disclosures they mirror, re-scored through the guarded pipeline under pinned code 9196601.
Initial public score 51 (publish-draft)
The formula and all 8 sources.
Same ten questions for every company. No private weighting.
SINK = (0.3 × Base + 0.7 × Performance) × Scale8 sources used in this assessment. All publicly available. Each row shows which of the ten questions it informed.
“In 2024, the total market-based Scope 1 and Scope 2 GHG emissions footprint was 24,662 tonnes of CO2e.”
“Data independently assured by ERM CVS; more details and the full assurance report are available in the 2024 Sustainability Report on pages 46–47.”
“Smith+Nephew received an A rating in the assessment, which evaluates corporate supply chain engagement practices on climate issues.”
“We are developing our Scope 3 emissions reduction roadmap in preparation for submitting this to the Science Based Target Initiative (SBTi) for validation.”
“we are mindful of the importance of biodiversity, particularly in some of the countries in which we operate including Costa Rica and Malaysia.”
“environmental violation $12,500 1 — Smith & Nephew Inc. — EPA — 2025”
“Smith & Nephew Inc., agreed to pay a $16.8 million fine to settle parallel criminal charges announced by the U.S. Department of Justice.”
“The 2024 Annual Report on Form 20-F was filed with the SEC earlier today.”
If you believe a source has been misread or a newer version exists, submit a challenge.
Smith & Nephew is a London-headquartered medical technology manufacturer founded in 1856, employing 11,000 people globally. It designs, manufactures and distributes surgical products, wound care, orthopaedic reconstruction, trauma devices, and advanced wound bioactives across 90+ countries. Mid-cap healthcare equipment supplier with diversified geographic footprint.
One email, every Sunday. Score changes, new research, the stories behind the numbers. Free.
No spam. Unsubscribe in one click.
Checking a company?
Search free →Asked to prove you're sustainable?
Get your business scored, free →Been scored?
See what's behind your number →Fees pay for the review, never the result.